Porter Health
Understanding Lp(a) - Lipoprotein(a)
The Genetic Cholesterol Risk Factor You Need to Know About
Lipoprotein(a), or Lp(a), is a type of cholesterol particle that carries an extra protein called apolipoprotein(a). It's similar to LDL ("bad" cholesterol) but much stickier and more dangerous for forming blood clots and plaques in arteries.
Why Lp(a) Is So Concerning:
It's genetic (inherited)
Your Lp(a) level is determined 70-90% by your genes. It doesn't change much with diet, exercise, or lifestyle.
It's common
About 1 in 5 people (20%) have elevated Lp(a), but most don't know it.
It greatly increases cardiovascular risk
Elevated Lp(a) doubles or triples your risk of heart attack, stroke, and aortic valve disease.
No proven treatment exists (yet)
Current medications don't lower Lp(a) effectively. Promising therapies are in clinical trials.
The Good News: Knowing your Lp(a) level helps you and your doctor make better treatment decisions - like being more aggressive about lowering LDL cholesterol and blood pressure.
Lp(a) is measured in nmol/L (nanomoles per liter) or mg/dL (milligrams per deciliter). Most labs use nmol/L:
Optimal (Low Risk)
< 30 mg/dL or < 75 nmol/L
Your Lp(a) is in the normal range. No additional cardiovascular risk from Lp(a).
Borderline High
30-50 mg/dL or 75-125 nmol/L
Moderately elevated. You may have slightly increased cardiovascular risk.
What to do:
- Optimize other risk factors (LDL, blood pressure, smoking)
- Consider more aggressive LDL target (< 70 mg/dL)
- Regular cardiovascular screening
High Risk
≥ 50 mg/dL or ≥ 125 nmol/L
Significantly elevated. 2-3x increased risk of cardiovascular events.
What to do:
- Very aggressive LDL target (< 70 mg/dL, ideally < 55 mg/dL)
- Consider high-intensity statin + ezetimibe
- Control all other risk factors aggressively
- Consider aspirin therapy (discuss with doctor)
- Test family members (Lp(a) is hereditary)
Very High Risk
≥ 100 mg/dL or ≥ 250 nmol/L
Extremely elevated. 3-4x increased cardiovascular risk. May also increase risk of aortic stenosis (heart valve disease).
Urgent Actions:
- Maximum LDL lowering (target < 55 mg/dL)
- Consider PCSK9 inhibitor if not at LDL goal with statin + ezetimibe
- Aspirin therapy (discuss benefits/risks with doctor)
- Regular cardiovascular screening (stress test, calcium score, echocardiogram)
- Test all first-degree relatives (parents, siblings, children)
- Consider enrollment in clinical trials for Lp(a)-lowering therapies
Test Once for Life:
Lp(a) is genetically determined and stays relatively constant throughout life. You only need to be tested once - usually no need to recheck unless there's a major change in health status.
Important for South Asian and High-Risk Populations:
If you have elevated Lp(a) AND you are of South Asian ancestry, have family history of premature CVD, or other risk factors, we recommend extra aggressive LDL lowering.
Why?
- Elevated Lp(a) is a non-modifiable genetic risk factor - you can't lower it with current medications
- South Asians with elevated Lp(a) face compounded risk - both genetic and ethnic factors working together
- The only proven strategy is to aggressively lower modifiable risk factors (LDL, blood pressure, lifestyle)
- Earlier intervention can prevent the increased lifetime risk from becoming reality
Action: Ethnicity-specific Lp(a) targets - South Asian: < 40 nmol/L, African American: < 50 nmol/L, General: < 75 nmol/L.
If your Lp(a) is elevated for your ethnicity, you CANNOT lower Lp(a) with current medications. Instead, focus on aggressively lowering LDL cholesterol to < 55 mg/dL (or even < 50 mg/dL for very high risk).
This may require high-intensity statin + ezetimibe, and potentially PCSK9 inhibitor therapy. Talk to your Porter Health coach about early screening (CAC score, stress testing) and enrollment in Lp(a)-lowering clinical trials.
Lp(a) increases cardiovascular disease risk through multiple mechanisms:
1. Atherosclerosis (Plaque Buildup)
Like LDL cholesterol, Lp(a) deposits cholesterol in artery walls. But Lp(a) is stickier and more prone to forming plaque that narrows arteries.
2. Blood Clot Formation
The apo(a) protein attached to Lp(a) looks similar to plasminogen, a protein that dissolves blood clots. Lp(a) interferes with clot breakdown, making clots more likely to form and stick around.
3. Inflammation
Lp(a) triggers inflammation in blood vessel walls, accelerating plaque growth and making plaques more unstable (more likely to rupture and cause heart attack/stroke).
4. Aortic Valve Disease
High Lp(a) increases risk of calcific aortic stenosis (hardening and narrowing of the aortic heart valve). This can eventually require valve replacement surgery.
Conditions Linked to Elevated Lp(a):
- Heart attack (myocardial infarction) - especially at young age
- Stroke (ischemic stroke)
- Peripheral artery disease (PAD)
- Aortic stenosis (heart valve disease)
- Sudden cardiac death
2026 ACC/AHA Guideline Recommendation:
Lp(a) measurement is now recommended at least once in all adults for cardiovascular risk assessment (Class 1 — strongest recommendation). Since Lp(a) is genetically determined and remains stable over your lifetime, one test is typically sufficient.
Lp(a) testing is especially important if you have:
Family history of premature heart disease
Heart attack or stroke in men < 55 or women < 65
Personal history of heart disease at young age
Especially if < 50 years old
Recurrent cardiovascular events despite treatment
Multiple heart attacks despite optimal LDL control
Family history of elevated Lp(a)
Lp(a) is hereditary — runs in families
High LDL despite healthy lifestyle
Familial hypercholesterolemia suspected
Unexplained stroke or peripheral artery disease
Especially at younger age
Aortic stenosis
To understand underlying cause
Borderline or intermediate cardiovascular risk
Elevated Lp(a) can tip the decision toward more aggressive treatment
If your Lp(a) is elevated (≥ 125 nmol/L or ≥ 50 mg/dL):
The 2026 guidelines recommend optimal early control of all modifiable cardiovascular risk factors — including LDL, blood pressure, blood sugar, and lifestyle. If you also have established cardiovascular disease and haven't met your LDL and non-HDL goals on statin therapy, adding a PCSK9 inhibitor is recommended.
The Hard Truth:
Currently, there is no FDA-approved medication proven to safely lower Lp(a) and reduce cardiovascular risk. Lifestyle changes (diet, exercise, weight loss) do NOT significantly lower Lp(a) because it's genetically determined.
Current Management Strategies
Since we can't lower Lp(a) effectively yet, the focus is on aggressively managing ALL other cardiovascular risk factors:
1. Very Aggressive LDL Lowering (Most Important!)
Target LDL < 70 mg/dL (ideally < 55 mg/dL) if Lp(a) is elevated.
- High-intensity statin (atorvastatin 40-80mg or rosuvastatin 20-40mg)
- Add ezetimibe if not at goal
- Consider PCSK9 inhibitor (evolocumab, alirocumab) if still not at goal
2. Blood Pressure Control
Target < 120/80 mmHg. High blood pressure + high Lp(a) = very high cardiovascular risk.
3. Aspirin Therapy (Discuss with Doctor)
Low-dose aspirin (81mg daily) may help prevent clots in those with very high Lp(a).
Caution: Aspirin increases bleeding risk. Discuss benefits vs. risks with your doctor.
4. Healthy Lifestyle
Even though lifestyle doesn't lower Lp(a), it still reduces overall cardiovascular risk:
- Don't smoke (or quit immediately)
- Exercise regularly (150 min/week)
- Eat a heart-healthy diet (Mediterranean diet)
- Maintain healthy weight
- Manage stress
5. Regular Screening
Monitor cardiovascular health more closely:
- Coronary calcium scan (to assess plaque buildup)
- Echocardiogram (to check for valve disease)
- Stress test (to detect blocked arteries)
Medications That Do NOT Lower Lp(a) Effectively
Statins: May slightly increase Lp(a) by 5-10% (but still recommended for LDL lowering)
Ezetimibe: No effect on Lp(a)
Fibrates: No significant effect on Lp(a)
PCSK9 inhibitors: May lower Lp(a) by 20-30% (currently being studied)
Niacin: Can lower Lp(a) by 20-30%, but not proven to reduce cardiovascular events (side effects limit use)
Promising Future Therapies (In Clinical Trials)
Antisense Oligonucleotides (ASOs)
Example: Pelacarsen (formerly AKCEA-APO(a)-LRx)
Injectable medication that reduces Lp(a) production in the liver by 80-90%.
Phase 3 trials ongoing. Results expected 2025-2026.
Small Interfering RNA (siRNA)
Example: Olpasiran (by Amgen)
Injectable medication given every 3-6 months that reduces Lp(a) by up to 95%.
Phase 3 trials ongoing. Extremely promising.
Ask your doctor: If you have very high Lp(a), ask about enrolling in clinical trials for Lp(a)-lowering therapies. Visit clinicaltrials.gov and search for "lipoprotein(a)".
Use this checklist to guide your conversation about Lp(a):
Lp(a) is a genetic cholesterol risk factor affecting 1 in 5 people (20%)
Elevated Lp(a) (≥ 50 mg/dL or ≥ 125 nmol/L) doubles or triples cardiovascular risk
Test once for life - Lp(a) is genetically determined and stays relatively constant
Lifestyle changes do NOT lower Lp(a) - it is 70-90% genetic
No FDA-approved medication currently lowers Lp(a) safely and effectively
Focus on very aggressive LDL lowering (< 55 mg/dL) to offset Lp(a) risk
Control all other risk factors: blood pressure, smoking, diabetes, weight
Consider aspirin therapy if Lp(a) is very high (discuss with doctor)
Test family members - Lp(a) runs in families
Promising therapies (ASOs, siRNA) in clinical trials may be available soon (2025-2026)
References:
Based on the 2026 ACC/AHA Guideline on the Management of Dyslipidemia and the 2022 AHA Scientific Statement on Lipoprotein(a) and Cardiovascular Disease. This guide translates the latest clinical guidelines into patient-friendly language to help you understand Lp(a).
Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026. doi:10.1016/j.jacc.2025.11.016
Virani SS, Morris PB, Agarwala A, et al. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia. J Am Coll Cardiol. 2021;78(9):960-993. doi:10.1016/j.jacc.2021.06.011